[go: up one dir, main page]

DK1581251T3 - Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf - Google Patents

Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf

Info

Publication number
DK1581251T3
DK1581251T3 DK03808602.1T DK03808602T DK1581251T3 DK 1581251 T3 DK1581251 T3 DK 1581251T3 DK 03808602 T DK03808602 T DK 03808602T DK 1581251 T3 DK1581251 T3 DK 1581251T3
Authority
DK
Denmark
Prior art keywords
crystals
producing
methods
human growth
growth hormon
Prior art date
Application number
DK03808602.1T
Other languages
English (en)
Inventor
Chandrika Govardhan
Nazer Khalaf
Benjamin Paul Simeone
Original Assignee
Althea Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Althea Tech Inc filed Critical Althea Tech Inc
Application granted granted Critical
Publication of DK1581251T3 publication Critical patent/DK1581251T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
DK03808602.1T 2002-12-31 2003-12-31 Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf DK1581251T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43751902P 2002-12-31 2002-12-31
US51704203P 2003-11-03 2003-11-03
PCT/US2003/041545 WO2004060310A2 (en) 2002-12-31 2003-12-31 Human growth hormone crystals and methods for preparing them

Publications (1)

Publication Number Publication Date
DK1581251T3 true DK1581251T3 (da) 2016-06-27

Family

ID=32717908

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03808602.1T DK1581251T3 (da) 2002-12-31 2003-12-31 Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf

Country Status (12)

Country Link
US (1) US9376479B2 (da)
EP (2) EP1581251B1 (da)
JP (2) JP4686361B2 (da)
KR (1) KR20050090430A (da)
AU (2) AU2003303646B2 (da)
BR (1) BR0317888A (da)
CA (1) CA2512052C (da)
DK (1) DK1581251T3 (da)
MX (1) MXPA05007181A (da)
RU (1) RU2357750C2 (da)
SG (1) SG176314A1 (da)
WO (1) WO2004060310A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1581251T3 (da) 2002-12-31 2016-06-27 Althea Tech Inc Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf
WO2004060920A1 (en) * 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
US20090029911A1 (en) * 2003-09-25 2009-01-29 Ashley Martin Williams Liquid Human Growth Hormone Formulation Containing Polyethylene Glycol
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1888117A1 (en) * 2005-05-25 2008-02-20 Novo Nordisk A/S Stabilized polypeptide formulations
WO2006125763A1 (en) 2005-05-25 2006-11-30 Novo Nordisk A/S Stabilized polypeptide formulations
CA2634053A1 (en) * 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
EP2647712A3 (en) 2006-08-04 2013-11-20 Baxter International Inc Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
MX2009002314A (es) * 2006-08-31 2009-03-20 Novartis Ag Composiciones farmaceuticas que comprenden hgh para suministro oral.
EP2486916B1 (en) 2006-12-18 2015-04-01 Ajinomoto Althea, Inc. Human growth hormone formulations
US8367412B2 (en) 2007-02-23 2013-02-05 Kwansei Gakuin Educational Foundation Protein crystallizing agent and method of crystallizing protein therewith
US20110091992A1 (en) * 2007-07-10 2011-04-21 Medimmune, Llc CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT
EP2111871A1 (de) * 2008-04-26 2009-10-28 Sandoz AG Stabilisierte Flüssigformulierung
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
CA2753641C (en) * 2009-02-25 2014-09-16 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
MX362286B (es) 2011-11-18 2019-01-10 Regeneron Pharma Microparticulas de polimero y proteina.
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3064213A4 (en) * 2013-10-28 2017-04-26 Terumo Kabushiki Kaisha Protein aqueous suspension
SI3230309T1 (sl) 2014-12-10 2023-08-31 Opko Biologics Ltd. Postopki za proizvodnjo dolgo delujočih, s CTP-spremenjenih polipeptidov rastnega hormona
US10960058B2 (en) 2015-06-19 2021-03-30 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
EA036623B1 (ru) * 2015-10-16 2020-12-01 Ридженерон Фармасьютикалз, Инк. Стабильные белковые композиции
IL264208B2 (en) 2016-07-11 2025-02-01 Opko Biologics Ltd Long-acting clotting factors and methods for their preparation
JP7104929B2 (ja) * 2017-07-24 2022-07-22 テルモ株式会社 医療用タンパク質とポリアミノ酸とを含む複合体の製造方法および医療用タンパク質とポリアミノ酸とを含む複合体
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB643268A (en) 1944-04-04 1950-09-15 Nordisk Insulinlab Improved process for the preparation of prolonged effect insulin products
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5618697A (en) 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
IL79681A (en) 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
ATE82506T1 (de) 1987-08-21 1992-12-15 Imcera Group Inc Stabilisierung von wachstumshormonen.
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5084350A (en) * 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
NL9000634A (nl) * 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
DK0454044T3 (da) * 1990-04-25 1996-04-22 Hoechst Ag Farmakologisk præparat indeholdende polyelektrolytkomplekser på mikropartikelform og mindst et virksomt stof
PL166045B1 (pl) 1990-06-04 1995-03-31 Schering Corp Sposób wytwarzania krystalicznego I nterferonu alfa-2 PL PL PL PL
US5780599A (en) * 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
DK168790D0 (da) 1990-07-13 1990-07-13 Novo Nordisk As
EP0565618A4 (en) 1991-01-03 1994-06-29 Alkermes Inc Stabilization of proteins by cationic biopolymers
DE4132005A1 (de) * 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
AU667503B2 (en) 1991-12-20 1996-03-28 Novo Nordisk Health Care Ag A stabilized pharmaceutical formulation comprising growth hormone and histidine
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5198422A (en) 1992-06-11 1993-03-30 Smithkline Beecham Corporation Stabilized somatotropin for parenteral administration
CA2489978A1 (en) 1992-07-31 1994-02-17 Genentech, Inc. Human growth hormone aqueous formulation
SE9302278D0 (sv) 1992-10-28 1993-07-02 Kabi Pharmacia Ab Growth hormone
DE69329295T2 (de) * 1992-12-02 2001-03-15 Alkermes Controlled Therapeutics, Inc. Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
NZ262634A (en) * 1993-02-23 1997-02-24 Genentech Inc Stabilizing polypeptides against degradation by organic solvents by admixing the peptide with trehalose or mannitol
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
WO1996007399A1 (en) 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Sustained release preparation containing metal salt of a peptide
US5439643A (en) * 1993-11-03 1995-08-08 Liebert; Richard T. Method and apparatus for terminal sterilization
US5610134A (en) 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5582591A (en) 1994-09-02 1996-12-10 Delab Delivery of solid drug compositions
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
ZA96122B (en) 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
JPH10511964A (ja) 1995-01-13 1998-11-17 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン及びＸ−Ｌｙｓを含む安定化医薬製剤
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5788959A (en) * 1995-04-24 1998-08-04 University Of Maryland, Baltimore County Drug delivery device and method for employing the same
ATE268591T1 (de) 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
ATE236929T1 (de) 1995-07-25 2003-04-15 Novartis Pharma Gmbh Transformierenden waeckstumsfaktor beta krystalle
AU718439B2 (en) * 1995-09-21 2000-04-13 Genentech Inc. Human growth hormone variants
US5972331A (en) * 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US7276251B2 (en) 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
US5932212A (en) * 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents
DE69700561T2 (de) * 1996-06-14 2000-05-04 Takeda Chemical Industries, Ltd. Verfahren zur Entfernung von N-Terminalem Methionin
EP0819758B1 (en) 1996-07-16 2006-09-20 Archibald James Mixson Cationic vehicle: DNA complexes and their use in gene therapy
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
EP0954282B1 (en) 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
SE9700566D0 (sv) 1997-02-18 1997-02-18 Pharmacia & Upjohn Ab Modified proteins
DK1009759T3 (da) 1997-09-05 2008-08-04 Altus Pharmaceuticals Inc Carbohydrat-tværbundne glycoproteinkrystaller
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
CA2315103A1 (en) 1997-12-18 1999-06-24 Eli Lilly And Company Crystalline teriparatide
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
EP2311436A1 (en) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
CA2330476A1 (en) 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6369118B1 (en) * 1998-09-09 2002-04-09 University Of Pittsburgh Biocompatible emulsifier
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
DE20023081U1 (de) 1999-06-10 2003-01-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 80539 München Eingekapselte Kristalle mit Mehrlagenbeschichtung
US6645525B1 (en) 1999-06-23 2003-11-11 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
ATE289630T1 (de) 1999-09-09 2005-03-15 Curevac Gmbh Transfer von mrnas unter verwendung von polykationischen verbindungen
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US20040006473A1 (en) 2002-07-02 2004-01-08 Sbc Technology Resources, Inc. Method and system for automated categorization of statements
US6417237B1 (en) * 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
US7037889B2 (en) 2000-09-13 2006-05-02 Praecis Pharmaceuticals Inc. Pharmaceutical compositions for sustained drug delivery
US7259233B2 (en) 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
KR20100031769A (ko) 2000-12-28 2010-03-24 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
WO2002053174A2 (en) * 2000-12-29 2002-07-11 Pbl Biomedical Laboratories Controlled release pharmaceutical systems
EP1250233A1 (en) 2001-01-09 2002-10-23 Encad, Inc. Ink jet printhead quality management system and method
EP1448222A4 (en) 2001-10-19 2006-05-17 Lilly Co Eli BIPHASIC MIXTURES OF GLP-1 AND INSULIN
CA2466054C (en) 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
AU2003221699A1 (en) * 2002-04-09 2003-10-27 Taisho Pharmaceutical Co., Ltd. Pharmaceutical preparation for taste masking
WO2004060920A1 (en) * 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
DK1581251T3 (da) 2002-12-31 2016-06-27 Althea Tech Inc Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf

Also Published As

Publication number Publication date
CA2512052C (en) 2016-06-21
MXPA05007181A (es) 2006-04-07
US20040209804A1 (en) 2004-10-21
CA2512052A1 (en) 2004-07-22
KR20050090430A (ko) 2005-09-13
RU2357750C2 (ru) 2009-06-10
WO2004060310A8 (en) 2005-06-02
JP2006512416A (ja) 2006-04-13
JP2010209079A (ja) 2010-09-24
EP1581251A2 (en) 2005-10-05
US9376479B2 (en) 2016-06-28
WO2004060310A3 (en) 2004-12-09
JP4686361B2 (ja) 2011-05-25
AU2003303646B2 (en) 2010-03-04
WO2004060310A2 (en) 2004-07-22
EP1581251B1 (en) 2016-03-16
EP1581251A4 (en) 2009-03-04
RU2005124280A (ru) 2006-01-20
AU2003303646A1 (en) 2004-07-29
AU2010201961A1 (en) 2010-06-03
SG176314A1 (en) 2011-12-29
EP2460530A3 (en) 2012-08-29
EP2460530A2 (en) 2012-06-06
BR0317888A (pt) 2005-12-06

Similar Documents

Publication Publication Date Title
DK1581251T3 (da) Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1299323T3 (da) Gødningsmiddel med styret frigivelse og fremgangsmåde til fremstilling deraf
DK1524710T3 (da) Tynd batteristruktur, batterienhed og fremgangsmåde til fremstilling af batterienhed
DK1673104T3 (da) Fremføring af terapeutiske forbindelser til hjernen og andre væv
IS8305A (is) Bindandi smíðar og aðferðir við notkun þeirra
IS7467A (is) Lansóprasólfjölgervingar og aðferðir við að framleiða þá
IS7344A (is) Stýrð efnasmíði síprasídóns og samsetninga af því
DK1440908T3 (da) Indsats og fremgangsmåde til fremstilling af drikkevarer
IS7966A (is) Pyrazól og aðferðir við að búa þau til og notkun þeirra
DK1542710T3 (da) Fremgangsmåde til konservering af organer og væv
GB2385328B (en) Crystals of glucokinase and methods of growing them
IS7977A (is) Samsetningar og aðferð til samsettra meðferðar
IS8061A (is) Kerfi og aðferð við að framleiða sérsniðna fóðringu fyrir gervilimi
NO20035669D0 (no) Kvartsglassdigel og fremgangsmåte for fremstilling derav
IL207054A0 (en) Single crystal diamond and method of making thereof
IS7645A (is) Stillar glúkósteraviðtaka og aðferð
DK1423102T3 (da) Plaster til behandling af neglevæksts dysfunktioner og lidelser
DK1357025T3 (da) Skæreindretning og fremgangmåde til skæring
IL176089A0 (en) Modified macromolecules and methods of making and using thereof
IS7725A (is) Imidazólópyridín og aðferðir við framleiðslu og notkun þeirra
IS7699A (is) Afleiður af díoxan-2-alkýl karbamötum, framleiðslu aðferð þeirra og notkun við meðferð sjúkdóma
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
DK2305689T3 (da) Syntese af naturligt forekommende ecteinascidiner og relateredeforbindelser
NO20030843D0 (no) Anordning og fremgangsmåte for kultivering